Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $7,816 | $9,655 | $7,991 | $12,957 |
| - Cash | $5 | $824 | $1,644 | $187 |
| + Debt | $326 | $577 | $1,770 | $720 |
| Enterprise Value | $8,137 | $9,408 | $8,117 | $13,490 |
| Revenue | $0 | $0 | $0 | $849 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | -$52 | $633 |
| % Margin | – | – | – | 74.6% |
| EBITDA | -$1,999 | -$2,522 | -$3,037 | -$3,136 |
| % Margin | – | – | – | -369.4% |
| Net Income | -$2,106 | -$2,903 | -$2,864 | -$2,973 |
| % Margin | – | – | – | -350.2% |
| EPS Diluted | -0.19 | -0.34 | -0.45 | -0.52 |
| % Growth | 44.1% | 24.4% | 13.5% | – |
| Operating Cash Flow | -$1,102 | -$3,502 | -$1,631 | -$1,048 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,102 | -$3,502 | -$1,631 | -$1,048 |